RWD240 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ATEZOLIZUMAB OR PEMBROLIZUMAB IN STAGE II-IIIA NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥1% EXPRESSING IN TAIWAN

vs left-sided (37%) disease.Among 371 patients with de novo metastatic disease, 40% received primary surgery.Of 549 patients with metastatic disease, 76% experienced real-world progression within 2 years of diagnosis.Conclusions: This study revealed variability in clinical characteristics and biomarker testing among patients diagnosed with CRC in Japan, thereby highlighting opportunities to optimize care and align practices with clinical guidelines.Further research using EHR-derived datasets is crucial in advancing CRC research and informing healthcare decision making in Japan.